康臣藥業(01681.HK):新疆稅收優惠政策對集團未來十年利潤產生明顯效益
康臣藥業(01681.HK)公佈,新疆霍爾果斯經濟開發區公佈將企業所得稅優惠政策延長至2030年,即自2021年1月1日起至2030年12月31日止,公司附屬康臣藥業(霍爾果斯)屬於《新疆困難地區重點鼓勵發展產業企業所得稅優惠目錄》,可以自取得第一筆生產經營收入所屬納稅年度起,5年內免徵企業所得稅,在享受五年免徵企業所得稅後,第六年至第十年進一步免徵企業所得稅地方分享部分。
公司認爲,稅收優惠政策對集團未來十年的整體利潤回報產生明顯的效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.